Sep 7 2010
Patrick S. Smith, President and Chief Executive Officer of Curaxis Pharmaceutical Corp. (OTCBB:CURX), announced today that the Financial Industry Regulatory Authority ("FINRA") has approved the change of the company's trading symbol on the OTCBB market from ASCH to CURX effective immediately.
Mr. Smith noted, "We are pleased that FINRA has approved the change of our trading symbol to CURX. As we ramp up our efforts to launch a Phase 2b trial in women of our Alzheimer's disease candidate, we are excited about the opportunity to produce compelling data such as that obtained in our earlier Phase 2a trial in women suffering from mild-to-moderate Alzheimer's. Based on that earlier data, we believe Memryte could be the first disease modifying treatment for Alzheimer's disease."
SOURCE Curaxis Pharmacutical Corp.